Biotech

All Articles

iTeos- GSK's TIGIT celebrity reveals meaningful remodeling

.After declaring a period 3 launch based upon favorable midstage results, iTeos and also GSK are las...

More collaborative FDA can easily speed up unusual health condition R&ampD: record

.The FDA must be more open and also collaborative to release a rise in approvals of rare illness med...

Zenas, MBX, Bicara head to Nasdaq in hot time for biotech IPOs

.It's an uncommonly active Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Rehabs all ...

Atea's COVID antiviral falls short to halt hospitalizations in period 3

.Atea Pharmaceuticals' antiviral has neglected one more COVID-19 trial, however the biotech still st...

Neurocrine's offer to spare schizophrenia possibility fails

.Neurocrine Biosciences' mental illness plan pivot has actually fallen short. The biotech was actual...

Sanofi pays $110M upfront for late-stage radioligand treatment

.Sanofi has brought in an overdue entry to the radioligand gathering, spending 100 thousand european...

F 2G raises $100M for second try to get new antifungal to market

.After F2G's initial attempt to obtain a brand-new class of antifungal to market was derailed by the...

Moderna targets $1.1 B in R&ampD investing slices, drops 5 programs in the middle of earnings pressures

.Moderna has sworn to cut R&ampD investing by $1.1 billion by 2027. The decision to shrink the spend...

Sanofi's $80M bet on Pivot dystrophy medication ends in phase 3 crash

.Only 4 months after Sanofi bet $80 million in beforehand cash on Pivot Therapeutics' losmapimod, th...

Oncternal equity sinks 60% among unemployments, test firings

.Cancer cells provider Oncternal Rehabs is folding all its professional tests and also giving up sta...